Welcome to our dedicated page for SENZIME AB ORD news (Ticker: snzzf), a resource for investors and traders seeking the latest updates and insights on SENZIME AB ORD stock.
Senzime AB ORD (SNZZF) is a leading medical device company headquartered in Sweden, specializing in perioperative precision-based patient monitoring solutions. Senzime has recently secured major public tender contracts with the US Department of Veterans Affairs and a prominent children's hospital system in the US for its TetraGraph System, a quantitative neuromuscular monitoring technology used by anesthesiologists worldwide. The company's innovative portfolio of solutions aims to enhance patient safety and reduce healthcare costs associated with surgical procedures.
Senzime reported strong Q3 2024 financial results with net sales of 17.4 MSEK, up 90% year-over-year. Sales of disposable sensors surged 169% to 12.5 MSEK, while US sales grew 81% to 13.1 MSEK. The company's TetraGraph system has been installed in over 500 hospitals globally. Despite growth, operating costs increased to 38.4 MSEK, resulting in an operating loss of 26.5 MSEK. The company recently launched its next-generation TetraGraph at ANESTHESIOLOGY 2024, featuring Adaptive Intelligence technology. Cash position stood at 50.2 MSEK as of September 30, 2024.
Senzime AB has announced changes in its share structure during October 2024. The company completed a directed share issue of 12,769,000 shares, increasing the total number of shares from 119,705,523 to 132,474,523. The share capital has risen to SEK 16,559,315.375 from SEK 14,963,190.375. An additional 1,104,000 shares from another directed share issue are pending registration following approval at the extraordinary general meeting on October 23, 2024. The company currently holds no treasury shares.
Senzime (SNZZF) has announced a webcast presentation of its Q3 2024 report scheduled for November 6, 15:00 CET. The report will be published earlier the same day. CEO Philip Siberg will lead the presentation, followed by a Q&A session moderated by Carnegie Investment Bank analyst Klas Palin. The presentation will be conducted in English and last 30 minutes. Participants can submit questions in advance via email to the moderator before 12:00 CET on November 6. The presentation will be available on Senzime's investor relations website.
Senzime has unveiled its next-generation TetraGraph® system at ANESTHESIOLOGY® 2024, featuring advanced monitoring capabilities for neuromuscular block during surgery. The system includes TetraGraph® Adaptive Intelligence™, offering automated workflows and real-time data monitoring. Key improvements include a revolutionary user interface with Level-of-Block Gauge™ and a 6th generation EMG algorithm with 4x higher resolution. The company announced that U.S. shipments will begin in Q4 2024, with the system designed to reduce complications from residual neuromuscular block in surgical patients.
At Senzime AB's extraordinary general meeting on October 23, 2024, shareholders unanimously approved the board's resolution for a directed share issue originally decided on September 27, 2024. The issue comprises a maximum of 1,104,000 shares at a subscription price of SEK 6.20 per share, with subscription rights granted to Adam Dahlberg and Sorin J. Brull. This will increase the company's share capital by up to SEK 138,000. The subscription deadline is set for October 28, 2024, and payment must be made in cash.
Senzime has secured its first order for the next-generation TetraGraph system from a Swiss hospital, comprising 20 monitors for Q1 2025 delivery with expected revenues of SEK 3 million over three years, including disposable sensors. The system, launched at ANESTHESIOLOGY 2024, features advanced monitoring capabilities including the Level-of-Block Gauge™, Adaptive Intelligence™, and an improved EMG algorithm with 4x higher resolution. The technology aligns with new clinical guidelines requiring quantitative monitoring of neuromuscular blocking drugs used in approximately 100 million surgical procedures annually.
A new US-based clinical study has validated the accuracy of Senzime's TetraGraph system, a neuromuscular monitoring device. The study, published on October 18, 2024, in the Journal of Clinical Monitoring and Computing, compared the TetraGraph to benchmark mechanomyography (MMG) technology. Key findings include:
1. The TetraGraph demonstrated 97.9% accuracy compared to MMG.
2. It is the first study to clinically validate a portable EMG-only system at all levels of neuromuscular block.
3. Results suggest TetraGraph's performance is superior to other commercially available neuromuscular monitoring systems.
4. The study was conducted at the Medical College of Wisconsin, led by Prof. Thomas Ebert.
Senzime's Chief Medical Officer, Dr. Sorin J. Brull, emphasized the importance of the TetraGraph's precision, particularly during laparoscopic and robotic surgeries. The researchers concluded that EMG monitors like TetraGraph should become a clinical standard for all phases of neuromuscular block.
Senzime AB announces the launch of its next-generation TetraGraph system at the ANESTHESIOLOGY 2024 conference in Philadelphia. The new system features TetraGraph Adaptive Intelligence™, a suite of smart algorithms for precision-based monitoring and automated workflows. It also includes a revolutionary user interface with the TetraGraph Level-of-Block Gauge™ and a 6th generation EMG-algorithm with 4x higher resolution for improved clinical accuracy.
The system, developed in collaboration with leading anesthesiologists, is engineered using sustainable materials and manufactured in an ISO14001 certified process. It will be marketed alongside the classic TetraGraph introduced in 2019. Customer deliveries will begin in the US during Q4 2024, in Europe during Q1 2025, and other global regions throughout 2025.
Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) has announced an extraordinary general meeting to be held on 23 October 2024 at 10.00 at Advokatfirman Lindahl's premises in Uppsala. Shareholders must be registered in the Euroclear Sweden AB share register by 15 October 2024 and notify their intention to attend by 18 October 2024.
The main agenda item is to approve the board's resolution on a directed share issue of up to 1,104,000 new shares at SEK 6.20 per share, potentially raising SEK 6,844,800. The issue is directed to Adam Dahlberg (700,000 shares) and Sorin J. Brull (404,000 shares), deviating from shareholders' pre-emption rights. The board cites the need for capital and the opportunity to attract strong investors on favorable terms as reasons for this approach.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) has secured an initial purchasing contract with a hospital of a top 5 US-based Integrated Delivery Network (IDN) on the US East Coast. The contract includes the installation and use of Senzime's TetraGraph neuromuscular system in all operating rooms, following a comprehensive clinical and competitive evaluation.
CEO Philip Siberg highlighted this as a strategic win, demonstrating Senzime's position as a leader in the rapidly transitioning US market for EMG-based neuromuscular monitoring. The contract opens doors to one of the top 5 leading IDNs in the US, with an addressable market potential of over 100,000 patients annually.
TetraGraph is a quantitative train-of-four monitoring system used by anesthesiologists worldwide, meeting recent US and European guidelines for monitoring patients receiving paralytic drugs. It aids in determining correct dosages and post-surgery recovery.
FAQ
What is the current stock price of SENZIME AB ORD (snzzf)?
What is the market cap of SENZIME AB ORD (snzzf)?
What is Senzime AB ORD known for?
What recent achievements has Senzime AB ORD made?
Where is Senzime AB ORD headquartered?
What market opportunity does Senzime AB ORD target?
What is the goal of Senzime AB ORD's patient monitoring solutions?
